Table 3.

Ongoing trials of ipilimumab plus nivolumab in Metastatic and Microsatellite Stable CRC.

End Time	Enrollment	Trial Phase	Primary Endpoints	Treatment Arms	Clinical Trials Identifier
2021	32	1	To determine the recommended dose level of the combination of regorafenib, nivolumab, and ipilimumab in patients with advanced metastatic RCC	Patients receive regorafenib on days 1–21, nivolumab, and ipilimumab IV. Cycles repeat every 28 days for up to 2 years	NCT04362839
2022	100	2	The 8-month PFS rate	Temozolomide 150 mg/sqm daily on days 1–5 every 4 weeks, for two cycles followed by TC scan assessment, nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide	NCT03832621
2025	494	3	PFS (Time Frame: Up to 5 years)	Arm A: Nivolumab Monotherapy Arm B: Nivolumab + Ipilimumab Combination Arm C: Investigator’s Choice Chemotherapy	NCT04008030
2024	80	2	Disease control rate (Time Frame: 2 years)	Nivolumab (3 times per cycle) +Ipilimumab (once per cycle) Radiation Therapy	NCT03104439